Mohsin Shah, MBBS, MSCE

Associate Director, Global Integrated Evidence - Epidemiology & RWE - Oncology

Mohsin Shah is the Associate Director of Global Integrated Evidence - Epidemiology & RWE Oncology at Boehringer Ingelheim, where he collaborates cross-functionally to assist in the development of strategies and real-world studies to enhance clinical development, add to regulatory submissions, inform payer interactions, and respond to changes in the marketplace, and enhance internal decision making. Dr. Shah is a clinical pharmacoepidemiologist by training with over eight years of experience conceptualizing, designing, and leading real-world studies. He has published over 26 peer-reviewed articles and presented over 20 conference presentations. Dr. Shah completed a T-32-funded postdoctoral fellowship in applied pharmacoepidemiology and graduated with a Master of Science in Clinical Epidemiology (MSCE) degree from the Perelman School of Medicine, University of Pennsylvania. Before this training, he completed a postdoctoral fellowship in internal medicine and oncologic emergency medicine at the UT MD Anderson Cancer Center. He received his medical doctorate from the University of Health Sciences. Dr. Shah’s expertise lies in (a) evaluating novel interventions using real-world data and state-of-the-art biostatistical and missing data methods (b) generating real-world evidence from such novel interventions, and (c) optimizing pharmacoepidemiology research methods to adapt to patients with cancer.

Alternate email: mohsin.shah@boehringer-ingelheim.com